Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Patients Undergoing Percutaneous Coronary Intervention Response
Circulation - United States
doi 10.1161/01.cir.102.25.e186
Full Text
Open PDFAbstract
Available in full text
Date
December 19, 2000
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)